Physician profile
Lindsay E Murrell
NPI 1437600889
$7,182.62
in general payments reported to CMS, 2019-2025
47 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,369 · 2023: $1,225 · 2024: $1,646 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,531.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.93 | 2021-2025 | |
| Lilly USA, LLC | $567.24 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Sk Life Science, INC. | $383.48 | 2021-2025 | |
| Lundbeck LLC | $357.75 | 2021-2025 | Vyepti, Rexulti |
| Amgen INC. | $343.10 | 2021-2025 | Aimovig, Uplizna |
| Eisai INC. | $336.98 | 2021-2025 | |
| Pfizer INC. | $331.36 | 2022-2025 | |
| Neurelis, INC. | $314.77 | 2021-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $252.68 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $242.22 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Octapharma USA, INC. | $233.65 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Neurocrine Biosciences, INC. | $232.69 | 2022-2025 | Ingrezza, Ongentys |
| Catalyst Pharmaceuticals, INC. | $197.80 | 2023-2025 | Fycompa |
| Kyowa Kirin, INC. | $183.14 | 2021-2024 | Nourianz |
| Ucb, INC. | $171.23 | 2021-2024 | Nayzilam |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $157.42 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $151.81 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $141.87 | 2021 | |
| Biogen, INC. | $141.49 | 2021-2023 | Skyclarys |
| Acadia Pharmaceuticals INC | $123.54 | 2022-2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $119.29 | 2021-2025 | Amvuttra |
| Amneal Pharmaceuticals LLC | $110.76 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Argenx US, INC. | $103.08 | 2023-2024 | Vyvgart |
| Corium, LLC | $75.19 | 2022-2023 | Adlarity |
| Astrazeneca Pharmaceuticals LP | $70.98 | 2023-2025 | Wainua |
| Tanabe Pharma America, INC. | $68.91 | 2022-2025 | Radicava |
| Avion Pharmaceuticals | $60.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $55.98 | 2021-2024 | Ultomiris |
| Averitas Pharma INC. | $54.35 | 2025 | Qutenza |
| Adamas Pharmaceuticals, INC. | $51.84 | 2021 | |
| Axsome Therapeutics, INC. | $51.04 | 2025 | Symbravo |
| Emd Serono, INC. | $49.67 | 2023-2024 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $48.65 | 2021-2022 | |
| Janssen Biotech, INC. | $46.03 | 2025 | |
| Genentech USA, INC. | $45.12 | 2024-2025 | Ocrevus Zunovo, Evrysdi |
| Avanir Pharmaceuticals, INC. | $43.89 | 2021-2022 | |
| Aucta Pharmaceuticals, INC. | $38.25 | 2024-2025 | Motpoly Xr |
| Greenwich Biosciences, INC. | $37.54 | 2021 | |
| Jazz Pharmaceuticals INC. | $32.10 | 2024 | |
| Microtransponder, INC. | $31.03 | 2025 | |
| Livanova USA, INC. | $26.63 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $23.06 | 2023 | Gamunex-C |
| Impel Pharmaceuticals LLC | $20.83 | 2025 | Trudhesa |
| Scilex Pharmaceuticals INC. | $19.95 | 2025 | |
| Impel Pharmaceuticals INC. | $17.78 | 2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $17.06 | 2021 | |
| Almatica Pharma LLC | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Murrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.